Abstract:Cytotoxic chemotherapy is a common treatment for advanced prostate cancer. These tumors are also known to rely on angiogenesis, i.e., the growth of local microvasculature via chemical signaling produced by the tumor. Thus, several clinical studies have been investigating antiangiogenic therapy for advanced prostate cancer, either as monotherapy or combined with standard cytotoxic protocols. However, the complex genetic alterations promoting prostate cancer growth complicate the selection of the best chemotherapeutic approach for each patient's tumor. Here, we present a mathematical model of prostate cancer growth and chemotherapy that may enable physicians to test and design personalized chemotherapeutic protocols in silico. We use the phase-field method to describe tumor growth, which we assume to be driven by a generic nutrient following reaction-diffusion dynamics. Tumor proliferation and apoptosis (i.e., programmed cell death) can be parameterized with experimentally-determined values. Cytotoxic chemotherapy is included as a term downregulating tumor net proliferation, while antiangiogenic therapy is modeled as a reduction in intratumoral nutrient supply. Another equation couples the tumor phase field with the production of prostate-specific antigen, which is an extensively used prostate cancer biomarker. We prove the well-posedness of our model and we run a series of representative simulations using an isogeometric method to explore untreated tumor growth as well as the effects of cytotoxic chemotherapy and antiangiogenic therapy, both alone and combined. Our simulations show that our model captures the growth morphologies of prostate cancer as well as common outcomes of cytotoxic and antiangiogenic mono and combined therapy. Our model also reproduces the usual temporal trends in tumor volume and prostate-specific antigen evolution observed in previous studies.

Mathematical Modeling and Analysis of Tumor Growth in response to a Mixed Chemotherapy and Immune Checkpoint Inhibition Therapy

Mathematical model of tumor immune microenvironment with application to the combined therapy targeting the PD-1/PD-L1 pathway and IL-10 cytokine antibody

Mathematical Modeling and Analysis of Tumor Chemotherapy

Stability analysis of the high-tumor equilibrium of a tumor growth model in response to combination therapy involving 4-1BB and IL-12

Mathematical modeling and dynamic analysis of anti-tumor immune response

Data-driven mathematical modeling and quantitative analysis of cell dynamics in the tumor microenvironment

Modeling the dynamics of mixed immunotherapy and chemotherapy for the treatment of immunogenic tumor

Mathematical modeling of cancer treatment with radiation and PD-L1 inhibitor

Modeling three-dimensional invasive solid tumor growth in heterogeneous microenvironment under chemotherapy

Mathematical modeling of combined therapies for treating tumor drug resistance

Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy

Computational Modeling of 3D Tumor Growth and Angiogenesis for Chemotherapy Evaluation

Mathematical analysis and simulation study of a phase-field model of prostate cancer growth with chemotherapy and antiangiogenic therapy effects

A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach

Bifurcation Analyses and Hormetic Effects of a Discrete-Time Tumor Model

Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates

Mathematical Modeling of the Synergetic Effect between Radiotherapy and Immunotherapy

A biomathematical model of tumor response to radioimmunotherapy with $α$PDL1 and $α$CTLA4

Qualitative and Computational Analysis of a Mathematical Model for Tumor-Immune Interactions

In Silico Synergism and Antagonism of an Anti-Tumour System Intervened by Coupling Immunotherapy and Chemotherapy: a Mathematical Modelling Approach.

Investigation of cancer response to chemotherapy: a hybrid multi-scale mathematical and computational model of the tumor microenvironment